PHARMACEUTICS INTERNATIONAL, INC.

Jabil Expands Pharmaceutical Manufacturing Capabilities with Strategic Pii Acquisition

• Jabil strengthens its pharmaceutical development and manufacturing capabilities through the strategic acquisition of Contract Development and Manufacturing Organization (CDMO) Pharmaceutics International Inc. (Pii). • The acquisition brings extensive scientific expertise and comprehensive pharmaceutical services to Jabil's portfolio, enhancing its ability to support drug development customers. • This strategic move positions Jabil to offer expanded services in pharmaceutical development, manufacturing, and clinical trial support to meet growing industry demands.